Welcome to our dedicated page for Medicinova news (Ticker: MNOV), a resource for investors and traders seeking the latest updates and insights on Medicinova stock.
MediciNova, Inc. develops small-molecule therapeutics for inflammatory, fibrotic, and neurodegenerative diseases. The company's recurring updates center on MN-166, or ibudilast, and MN-001, or tipelukast, including programs involving amyotrophic lateral sclerosis, degenerative cervical myelopathy, progressive multiple sclerosis, chemotherapy-induced peripheral neuropathy, Long COVID, substance dependence, non-alcoholic fatty liver disease, hypertriglyceridemia, and idiopathic pulmonary fibrosis.
MediciNova news also covers clinical-trial progress, expanded-access activity, investigator-sponsored research, peer-reviewed translational studies, scientific and regulatory advisory matters, and corporate updates connected to its Nasdaq-listed common stock and Tokyo Stock Exchange listing.
MediciNova, Inc. announced the receipt of a Notice of Intention to Grant from the European Patent Office for a pending patent application covering MN-001 (tipelukast) and its metabolite MN-002. This patent will address treatments for hypertriglyceridemia, hypercholesterolemia, and hyperlipoproteinemia, expiring no earlier than July 2034. The patent claims include methods for reducing triglyceride and cholesterol blood levels through oral administration. This development could enhance the potential market value of MN-001, complementing existing patents in the U.S., Japan, and China.